Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

25,729 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 7,369
Recruiting: 3,967
Ph III recruiting: 537
Growth YoY: +9.3%
Industry share: 25%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3,405)

clinicaltrialsPublishedShowing 901–950 of 11,047 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05466149	Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion	active not recruiting	Phase 2	100	Allist Pharmaceuticals, Inc.INDUSTRY	1	Aug 14, 2026	clinicaltrials
NCT05758116	Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients	completed	Phase 2	5	Peking University Cancer Hospital & InstituteOTHER	1	Aug 14, 2026